Labcorp Holdings Inc. (LH) is a Burlington, North Carolina-based global provider of laboratory services, diagnostics, and drug development solutions. The company serves physicians, hospitals, pharmaceutical companies, researchers, and patients, with operations spanning approximately 100 countries. Labcorp has a market cap of $25.3 billion.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and LH perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics and research industry, as it continues to expand through organic growth, acquisitions, and greater exposure to specialty testing and biopharma services.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
LH shares are currently down 8.9% from their 52-week high of $341.80, achieved on Aug. 27. Over the past three months, LH stock has gained 22.5%, outperforming the Dow Jones Industrial Average’s ($DOWI) marginal gains during the same time frame.
www.barchart.com Moreover, shares of LH rose 24.2% on a YTD basis and climbed 11.7% over the past 52 weeks, compared to DOWI’s YTD gains of 7.9% and 11.8% returns over the past year.
To confirm the bullish trend, LH has been trading above its 50-day and 200-day moving averages since late June with some occasional fluctuations.
www.barchart.com Labcorp stock has been supported in 2026 by improving financial results and a stronger earnings outlook. The company released its second-quarter 2026 results on July 30, reporting revenue of $3.7 billion, up 5.8% year-over-year (YOY), while adjusted EPS rose 14.9% to $4.99. Labcorp also raised its full-year 2026 revenue-growth guidance to 5.4%-6.3% and adjusted EPS guidance to $18.10-$18.55.
The company later reaffirmed this outlook at its Sept. 10 Investor Day, while laying out a longer-term target of 5%-8% annual revenue growth and 8.5%-11.5% adjusted EPS growth through 2029, supported by specialty diagnostics, biopharma services, technology, and innovation.
In the competitive arena, LH has performed better than Abbott Laboratories (ABT), which has slumped 17.2% on a YTD basis and 24.1% over the past year.
Wall Street analysts are bullish on LH’s prospects. The stock has a consensus “Strong Buy” rating from the 17 analysts covering it, and the mean price target of $348.24 suggests a potential upside of 11.8% from current price levels.
On the date of publication, Subhasree Kar did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
This High-Yield Tobacco Stock Just Raised Its Dividend by 8.8% America’s Tech Elite Are Sounding the Alarm on AI. They’re Also Already the Richest People in the World. Broadcom Just Named Its Next AI Customer. It Isn’t Google. Intel vs. TSMC: One Chip Stock Controls 72.5% of the Foundry Market. The Other Is Mounting a Comeback.